Journal of Postgraduate Medicine, Education and Research

Register      Login

VOLUME 47 , ISSUE 1 ( January-March, 2013 ) > List of Articles

REVIEW ARTICLE

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Suresh C Srivastava

Citation Information : Srivastava SC. A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals. J Postgrad Med Edu Res 2013; 47 (1):31-46.

DOI: 10.5005/jp-journals-10028-1054

Published Online: 00-03-2013

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Srivastava SC. A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals. J Postgrad Med Edu Res 2013;47(1):31-46.


PDF Share
  1. Paving the way to personalized medicine: Production of some promising theragnostic radionuclides at Brookhaven National Laboratory. Semin Nucl Med 2012;42: 151-63.
  2. Theragnostic radiopharmaceuticals: The ‘Janus’ approach to molecular diagnosis and therapy. CME session # 63 on Novel radiopharmaceuticals for molecular imaging and therapy–where are we headed next? Presented at 2009 SNM Annual Meeting, Toronto, Canada, June 15, 2009.
  3. Theragnostic radiometals: Getting closer to personalized medicine. In: Mazzi U, et al (Eds). Technetium and other radiometals in chemistry and nuclear medicine. Padova, Italy, SG Editorial 2010;553-68.
  4. Paving the way to personalized medicine: Production of some theragnostic radionuclides at Brookhaven National Laboratory. Radiochim Acta 2011;99:635-40.
  5. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 1993;34:2222-36.
  6. Radiolabeled monoclonal antibodies for imaging and therapy. New York: Plenum Press 1988;876.
  7. Recent advances in radionuclide therapy. Seminars in Nucl Med 2001;31:330-41.
  8. Improved quality of life in patients treated with peptide radionuclides. World J Nucl Med 2011;10:115-21.
  9. Lethality of Auger electrons from the decay of Br-77 in the DNA of mammalian cells. Radiat Res 1982;90:362-73.
  10. Radiobiologic implications of the microscopic distribution of energy from radionuclides. Nucl Med Biol 1987;14:165-69.
  11. Biological damage from the Auger effect: Possible benefits. Radiat Environ Biophys 1975;12:85-99.
  12. Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: Possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron. Appl Radiat Isotopes 1993;44:575-80.
  13. Radiochemical studies relevant to Y-86 production via 86Sr(p, n)86Y for PET imaging. Appl Radiat Isot 2009;67:7-10.
  14. Irradiation of strontium chloride targets at proton energies above 35 MeV to produce PET radioisotope Y-86. Radiochim Acta 2011;99: 755-61.
  15. Evaluation of excitation functions of 3He and α-particle induced reactions on antimony isotopes with special relevance to the production of iodine-124. Appl Radiat Isotopes 2001;69:94-104.
  16. Chemical and biological evaluation of scandium (III)-polyamino-polycarboxylate complexes as potential PET agent and radiopharmaceutical. Radiochim Acta 2011;99:653-62.
  17. Production of high specific activity Ge-68 at Brookhaven National Laboratory. J Radioanal Nucl Chemistry 2005;263:553-57.
  18. Production and evaluation of Sc-47 for radioimmunotherapy. J Labelled Compds Radiopharm 1993;32:388-90.
  19. Radiochemical purification of no-carrier-added Scandium-47 for radioimmunotherapy. Appl Radiat Isot 1998;49:1541-49.
  20. Scandium 47: A replacement for Cu-67 in nuclear medicine therapy with beta/gamma emitters. In: Stevenson N (Eds). Isotope production and applications in the 21st Century. London: World Scientific 2000;43-45.
  21. Production of nocarrier-added Cu-67. Int J Radiat Appl Instrum Part A, Appl Radiat Isot 1986;37:29-36.
  22. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res 1998;18:2779-88.
  23. 67Cu-2IT-BATLym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999; 40:302-10.
  24. Development of large scale production of Cu-67 from Zn-68 at the high energy accelerator: Closing the Zn-68 cycle. Int J Appl Radiat Isot 2012;70:423-29.
  25. Cancer therapy with alpha-emitters labeled peptides. Semin Nucl Med 2010;40:204-08.
  26. Targeted particle immunotherapy for myeloid leukemia. Blood 2002;100:1233
  27. Preclinical evaluation of the alpha-particle generator nuclide Ac-225 for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res 2008;14:3555
  28. Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha, 2n)211 at reaction. Appl Radiat Isot 1996;47: 135-43.
  29. High-level production of alpha-particle-emitting (211)At and preparation of (211) At-labeled antibodies for clinical use. J Nucl Med 2001;42:1508-15.
  30. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 2001;42:1538-44.
  31. The arronax project. Current Radiopharm 2011;4:186-96.
  32. An Ac-225/Bi-213 generator system for therapeutic clinical applications: Construction and operation. Applied Radiat Isot 1999;50:895
  33. Bi-213-DOTA(0), Tyr(3) octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clinical Cancer Res 2006;12:897
  34. The Feasibility of Ac-225 as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun 1993;14:121
  35. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews 2008;60:1371
  36. Enhanced retention of the alpha-particle-emitting daughters of actinium-225 by liposome carriers. Bioconj Chem 2007;18:2061
  37. J. Radioanal Nucl Chem 2009;280:329
  38. Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225. Cancer Biother Radiopharm 2006;21:40
  39. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot 2005;62:667
  40. Production of Ac-225 from Th-229 for targeted alpha therapy. Analytical Chem 2005;77:6288
  41. Production of 225Ac and 223Ra by irradiation of Th with accelerated protons. Radiochemistry 2011;53:73-80.
  42. Cyclotron and linac production of Ac-225. Appl. Radiat Isot 2009;67(4):549-55.
  43. Macrocyclic polyaminocarboxylates for radiometal antibody conjugates for therapy, SPECT and PET imaging. US Patent #5,639,879, June 17, 1997.
  44. Rigid bifunctional chelating agents. US Patent # 6,022,522, February 8, 2000.
  45. Nuclear data for production of 117mSn for biomedical application. In: Proceedings of the International Conference on Nuclear Data for Basic and Applied Science. Santa Fe: New Mexico 1985 May;733-37.
  46. Evaluation of neutron inelastic scattering for radioisotope production. Appl Radiat Isot 1997b;48:441-46.
  47. Reactor production of high-specific activity tin-117m for bone pain palliation and bone cancer therapy. J Nucl Med 2004;45:475
  48. Treatment of metastatic bone pain with tin-117m(4+)DTPA: A phase II clinical study. Clinical Cancer Res 1998;4:61-68.
  49. Production of no-carrier-added Tin-117m from proton irradiated antimony. J Radioanal Chem 2009;280:319-24.
  50. Production of carrier-free 117mSn. Int J Appl Radiat Isot 1984;35:645-50.
  51. Level and isomer systematics in even tin isotopes from Sn-108 to Sn-118 observed in Cd(α, xn) Sn reactions. Nucl Phys A 1969;134:81-109.
  52. Production of no-carrier-added Sn-117m at medium energy cyclotrons. Publication in Progress (2012).
  53. Marrow sparing effects of Sn-117m (4+) DTPA for radionuclide therapy of cancer in bone. J Nucl Med 2000;41:2043-50.
  54. The development and in vivo behavior of tin containing radiopharmaceuticals II: Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease. Int J Nucl Med Biol 1985;12:175-84.
  55. In vivo tissue uptake and retention of Sn-117m (4+) DTPA in a human subject with metastatic bone pain and in normal mice. Nucl Med Biol 1998;25:279-87.
  56. Intravascular stents electroplated with Sn-117m reduce arterial wall inflammation in hyperlipidemic rabbits. Atlanta, GA: Presented at the GLS 2007 Meeting, October 3, 2007 (abstr).
  57. Intravascular stents electroplated with 117mSn reduce arterial wall inflammation in hyperlipidemic rabbits. Chicago, IL: Presented at the 2008 ACC Annual Meeting, May, 2008 (abstr).
  58. Evaluation of tin-117m labeled Annexin V for imaging atherosclerotic lesions in a hyperlipidemic rabbit model. Publication in Progress (2013).
  59. Development and evaluation of tin-117m labeled Annexin for the imaging and treatment of vulnerable plaques. Publication in Progress (2013).
  60. Method of electroplating a conversion electron emitting source on implant. US Patent Application Serial No 11/758,914, Dec 22, 2011; Publication in Progress (2013).
  61. Theragnostic potential of Sn-117m for the molecular targeting and therapy of vulnerable plaque. Publication in Progress (2013).
  62. Therapeutic radionuclides: Making the right choice. In: Mather SJ (Eds). Current directions in radiopharmaceutical research and development. Dordrecht, The Netherlands: Kluwer Academic Publishers 1996;63-79.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.